Greg Garfield
Senior Managing Director @ KCK
Menlo Park, United States
Greg Garfield is a Series D investor at KCK in Menlo Park focused on Health Care and Medical Device. Greg is an executive with extensive experience in running medical technology companies, including managing and leading people at all levels, as well operational management and business strategy and planning.Originally an attorney at Pillsbury Winthrop, Greg began his medical technology career at Guidant Corporation where he held a number ofexecutive-level legal and business development positions in different Guidant operating companies. Following Guidant's acquisition by Boston Scientific, Greg joined Acclarent, Inc. where he served initially as Vice President of Corporate Development, and then as Acclarent's Chief Operating Officer through the acquisition and integration of Acclarent by Ethicon, Inc., a Johnson & Johnson company.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Greg Garfield invests in
Stages Greg Garfield invests in
Countries Greg Garfield invests in
Investment Focus
Industry
- Health Care 3 (43%)
- Medical Device 3 (43%)
- Medical 2 (29%)
- Neuroscience 1 (14%)
- Therapeutics 1 (14%)
Stage
- Series D 2 (29%)
- Series B 1 (14%)
- Series C 1 (14%)
- Series E 1 (14%)
- Funding Round 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RefleXion Medical
|
RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $80M / Series E / Mar 10, 2022 | |
NeuroPace
|
NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a shorttrain of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California. | $33M / Venture - Series Unknown / Aug 31, 2020 | |
|
RefleXion Medical
|
RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $100M / Series D / Apr 17, 2020 | |
Earlens
|
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $87M / Series D / Oct 22, 2018 | |
|
RefleXion Medical
|
RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $100M / Series C / Apr 04, 2018 | |
|
NeuroPace
|
NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a shorttrain of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California. | $74M / Oct 24, 2017 | |
|
RefleXion Medical
|
RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $52M / Series B / Apr 14, 2016 |
Co-Investors
About KCK
KCK is a family investment fund that invests in a diverse set of industries, including medical technologies. KCK interests in Life Sciences - Biopharm/ Biotech & MedTech, Energy, Science-rich companies and Industrial Technologies. KCK invest at all stages of a startup's from early stage to growth rounds and also invest in publiccompanies. KCK is the private equity arm of a family office which seeks to partner with experienced management teams, focused on niche markets, deploying long-term flexible capital to generate high risk-adjusted returns.
KCK Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Greg Garfield
Senior Managing Director
|
|||
|
Nael Kassar
Founder
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Greg Garfield invest in?
Greg Garfield invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Greg Garfield last invest?
The most recent investment recorded for Greg Garfield closed in Mar 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
